logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Regeneron: The Completed Acquisition of Checkmate Pharmaceuticals is Excellent News Not Bad News

Regeneron Pharmaceuticals Acquisition of Checkmate Pharmaceuticals  Regeneron Pharmaceuticals ( REGN ) announced a successful acquisition of Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology. The firm has added a new modality to the company's portfolio of potential combination-ready approaches for...

Read More

May 31, 2022

0

Reata Pharmaceuticals Submits MAA to the EMA for Chronic Kidney Disease Caused by Alport Syndrome

Reata Pharmaceuticals MAA Submission for Bardoxolone Methyl Reata Pharmaceuticals ( RETA ) announced the submission of a Marketing Authorization Application ( MAA ) for bardoxolone methyl to the European Medicines Agency ( EMA ) for chronic kidney disease ( CKD...

Read More

October 29, 2021

0

A First in Class Antibody for a Difficult to Treat Stomach Cancer and Maybe Others

Five Prime Therapeutics Antibody Plus Chemotherapy for Stomach Cancer Five Prime Therapeutics ( FPRX )  announced positive topline results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial compared mFOLFOX6 chemotherapy in combination with bemarituzumab ( bema, FPA144 ) - a first-in-class...

Read More

November 11, 2020

0

Reata Pharmaceuticals Third Quarter Financial Results and Other Company Updates

Reata Pharmaceuticals Business Operations and Clinical Development Updates Reata Pharmaceuticals ( RETA ) – a clinical-stage biopharmaceutical company announced financial results for the quarter ended September 30, 2021, and provided an update on the Company’s business operations and clinical development...

Read More

November 8, 2021

0

Merck and Ridgeback Biotherapeutics: U.S. Government to Purchase 1.4 M Additional Courses of Molnupiravir for COVID-19

U.S. Government to Purchase More of Merck and Ridgeback Biotherapeutics Molnupiravir for COVID-19 Merck ( MRK ) and Ridgeback Biotherapeutics announced that the United States government will exercise two of its options to purchase a total of 1.4 million additional...

Read More

November 9, 2021

0

Inovio to Proceed with Phase 2 Trial of INO-4800 Vaccine Candidate for COVID-19

Inovio Announced FDA Clearance to Proceed with Trial for COVID-19 Vaccine Candidate Inovio ( INO ) announced the receipt of the U.S. FDA clearance to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800,...

Read More

November 16, 2020

0

Why Gilead Sciences Product Lenacapavir Deserves the FDA Granted Breakthrough Therapy Designation. See Also: Cellectis and Sanofi

Gilead Sciences News Results from Phase 2/3 CAPELLA trial evaluating Gilead Sciences ( GILD )  lenacapavir achieved the primary endpoint in heavily treatment-experienced people with multidrug-resistant HIV-1 infection. The study showed that 88% of participants receiving lenacapavir experienced at least...

Read More

November 19, 2020

0

Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy for Type 1Diabetes

Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy CRISPR Therapeutics ( CRSP ) and ViaCyte, Inc. , announced that Health Canada approved their Clinical Trial Application ( CTA ) for the product VCTX210, an...

Read More

November 16, 2021

0

CureVac Lawsuit Against BioNTech and Subsidiaries, Seeking Fair Compensation for Infringement of Intellectual Property

CureVac N.V. Files Lawsuit Against BioNTech for Infringement  CureVac N.V. ( CVAC ), a company that develops therapeutics based on messenger ribonucleic acid ( mRNA ), has moved to assert its intellectual property rights that have been accumulated over more...

Read More

July 5, 2022

0

GlaxoSmithKline and Vir Biotechnology Announced U.S. Gov't Contracts to Purchase $1B of Sotrovimab for COVID-19

GlaxoSmithKline and Vir Biotechnology Announces US Gov't Contracts to Purchase Sotrovimab for COVID-19 GlaxoSmithKline plc ( GSK ) and Vir Biotechnology ( VIR ) announced US government contracts totaling around $1 billion (USD) to purchase sotrovimab - an investigational monoclonal...

Read More

November 17, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 127
  • 128
  • 129
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy